IN VIVO EFFECTS OF IL 2--ROLE OF TNF AND TNF R FAMILIES
IL 2 的体内作用——TNF 和 TNF R 家族的作用
基本信息
- 批准号:2683717
- 负责人:
- 金额:$ 19.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-04-01 至 2000-03-31
- 项目状态:已结题
- 来源:
- 关键词:CD40 molecule CD95 molecule cytokine cytokine receptors epidermal growth factor flow cytometry human tissue immunopharmacology interleukin 2 laboratory mouse leukocyte adhesion molecules neoplasm /cancer immunotherapy neoplasm /cancer remission /regression receptor expression surface antigens tissue /cell culture transforming growth factors tumor necrosis factor alpha vascular endothelium permeability western blottings
项目摘要
With the exception of TNF and LT (both of which are secreted),
members of the TNF family are membrane-associated T cell activation
antigens, several of which are induced by IL-2. Receptors of these
proteins (e.g. fas, CD40, the LT-beta receptor) are members of the
TNF receptor family known primarily for their roles in B cell help
(CD40), the induction of apoptosis (fas), or lymph node development
(the LT-beta-R). Fas, CD40, and theLT-beta receptor have recently
been demonstrated on the endothelium, where their functions are
largely unknown. However, like the p55 TNF receptor, CD40
engagement has been shown to elicit adhesion molecule expression in
these cells, thus raising the possibility that these TNF receptor family
members may transmit signals upon contact with activated lymphocytes
that are qualitatively similar to those induced by TNF itself. In
addition to fas and the p55 TNF receptor, both CD40 and the LT-beta
receptor were recently shown to transmit apoptotic signals in certain
tumor cell lines, suggesting that they may play a role in tumor cell
cytolysis mediated by IL-2-primed lymphocytes. The studies we have
proposed in this application will assess the ability of IL-2 to induce the
expression of membrane-associated TNF family members in various
lymphoid populations in vitro and in vivo. The factors regulating the
expression of their respective receptors (e.g. fas, CD40, the LT-beta
receptor) on cultured endothelial cells and on skin and tumor-associated
endothelium will also be determined. Several studies with tumor-
bearing mice are proposed to assess the role played by the fas-L,
CD40-L and 'membrane LT' present on IL-2-activated lymphocytes in
IL-2-induced tumor regression and endothelial injury. Ultimately,
these studies will address the feasibility of using fas-IgG, CD40-IgG,
LT-beta receptor-IgG fusion proteins to attenuate the microvascular
pathology resulting from the administration of IL-2.
除TNF和LT(两者都分泌)外,
TNF家族的成员是与膜相关的T细胞激活
抗原,其中几种是由IL-2诱导的。 这些受体
蛋白质(例如FAS,CD40,LT-BETA受体)是
TNF受体家族主要以其在B细胞帮助中的作用而闻名
(CD40),凋亡诱导(FAS)或淋巴结发展
(LT-BETA-R)。 FAS,CD40和Thelt-Beta受体最近具有
已在其功能的内皮上证明
在很大程度上未知。 但是,像p55 TNF受体CD40一样
已显示参与引起粘附分子的表达
这些细胞,从而增加了这些TNF受体家族的可能性
成员可以在与活化的淋巴细胞接触后传输信号
与TNF本身引起的那些相似。 在
在FAS和p55 TNF受体中,CD40和LT-Beta都
最近显示受体在某些人中传输凋亡信号
肿瘤细胞系,表明它们可能在肿瘤细胞中起作用
由IL-2蛋白酶淋巴细胞介导的细胞解析。 我们拥有的研究
在本应用中提出的将评估IL-2诱导的能力
各种膜相关的TNF家族成员的表达
体外和体内淋巴样群体。 调节的因素
表达各自的受体(例如FAS,CD40,LT-BETA
受体)在培养的内皮细胞以及皮肤和肿瘤相关的受体上
内皮也将确定。 几项关于肿瘤的研究
提出了轴承小鼠来评估FAS-L的作用,
在IL-2激活的淋巴细胞上存在CD40-L和“膜LT”
IL-2诱导的肿瘤消退和内皮损伤。 最终,
这些研究将解决使用FAS-IGG CD40-IGG的可行性,
LT-BETA受体-IGG融合蛋白可减轻微血管
由IL-2给药引起的病理学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES W MIER其他文献
JAMES W MIER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES W MIER', 18)}}的其他基金
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for
靶向 Raf 治疗黑色素瘤:作用机制
- 批准号:
7464270 - 财政年份:2008
- 资助金额:
$ 19.88万 - 项目类别:
PHASE I CLINICAL TRIAL OF DECITABINE PRIOR TO DACARBAZINE IN ADVANCED MELANOMA
达卡巴嗪治疗晚期黑色素瘤中地西他滨的 I 期临床试验
- 批准号:
7205190 - 财政年份:2005
- 资助金额:
$ 19.88万 - 项目类别:
IN VIVO EFFECTS OF IL 2--ROLE OF TNF AND TNF R FAMILIES
IL 2 的体内作用——TNF 和 TNF R 家族的作用
- 批准号:
2895972 - 财政年份:1997
- 资助金额:
$ 19.88万 - 项目类别:
IN VIVO EFFECTS OF IL 2--ROLE OF TNF AND TNF R FAMILIES
IL 2 的体内作用——TNF 和 TNF R 家族的作用
- 批准号:
2646453 - 财政年份:1997
- 资助金额:
$ 19.88万 - 项目类别:
相似海外基金
Immunological control of a persistent viral infection
持续性病毒感染的免疫控制
- 批准号:
6850009 - 财政年份:2003
- 资助金额:
$ 19.88万 - 项目类别:
Immunological control of a persistent viral infection
持续性病毒感染的免疫控制
- 批准号:
6861090 - 财政年份:2003
- 资助金额:
$ 19.88万 - 项目类别:
Immunological control of a persistent viral infection
持续性病毒感染的免疫控制
- 批准号:
6849438 - 财政年份:2003
- 资助金额:
$ 19.88万 - 项目类别:
Immunological control of a persistent viral infection
持续性病毒感染的免疫控制
- 批准号:
7008890 - 财政年份:2003
- 资助金额:
$ 19.88万 - 项目类别:
Immunological control of a persistent viral infection
持续性病毒感染的免疫控制
- 批准号:
6611485 - 财政年份:2003
- 资助金额:
$ 19.88万 - 项目类别: